Serum Microrna as a Marker of Multiple Myeloma
| Authors | |
|---|---|
| Year of publication | 2013 |
| Type | Conference abstract |
| Citation | |
| Description | MicroRNA (miRNA) are small non-coding RNA playing a significant role in pathogenesis of multiple myeloma (MM). We have identified a specific serum miRNA profile in MM patients (pts) and correlated it with clinical parameters. Methods. 133 serum samples: 103 (51M/52F) from newly diagnosed MM pts and 30 (14M/16F) from healthy donors (HD) were tested. A screening of 667 serum miRNA was performed on 4 MM and 4 HD with TaqMan Low Density Arrays (TLDA). Expression of differentially expressed miRNA was validated by RT-PCR. Area under curve (AUC), specificity, sensitivity and correlation with clinical parameters was analyzed.Results. Based on TLDA, 14 miRNA were differentially expressed between MM and HD (p<0.05). Out of them, five miRNA were validated by RT-PCR: miR-744 (p<0.0004), miR-130a (p<0.0002), let 7d (p<0.0001) and let-7e (p<0.0001) were significantly downregulated and miR-34a (p<0.0001) was significantly upregulated. ROC analysis showed highest sensitivity (80.6%), specificity (86.7%) and AUC (0.898) for a combination of miR-34a and let-7d. Positive correlation was observed between low levels of miR-744, let-7d and let-7e and levels of hemoglobin, thrombocytes and albumin (all p=0.0001), negative correlation between low miRNA levels and levels of creatinine and beta2 microglobulin was found (all p<0.0001). Expression of miR-744, let-7d and let-7e showed an inverse correlation with ISS stage (all p<0.0001).Conclusion. Our study shows that miRNA may be a promising biomarker for MM pts. |
| Related projects: |